MX2013007171A - Inductor de autofagia y terapia de combinacion inhibidora para el tratamiento de neoplasias. - Google Patents

Inductor de autofagia y terapia de combinacion inhibidora para el tratamiento de neoplasias.

Info

Publication number
MX2013007171A
MX2013007171A MX2013007171A MX2013007171A MX2013007171A MX 2013007171 A MX2013007171 A MX 2013007171A MX 2013007171 A MX2013007171 A MX 2013007171A MX 2013007171 A MX2013007171 A MX 2013007171A MX 2013007171 A MX2013007171 A MX 2013007171A
Authority
MX
Mexico
Prior art keywords
neoplasms
treatment
combination therapy
inhibitor combination
autophagy inducer
Prior art date
Application number
MX2013007171A
Other languages
English (en)
Spanish (es)
Inventor
Kui Lin
Michael Degtyarev
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2013007171A publication Critical patent/MX2013007171A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2013007171A 2010-12-23 2010-12-23 Inductor de autofagia y terapia de combinacion inhibidora para el tratamiento de neoplasias. MX2013007171A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2010/062096 WO2012087336A1 (en) 2010-12-23 2010-12-23 Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms

Publications (1)

Publication Number Publication Date
MX2013007171A true MX2013007171A (es) 2013-11-04

Family

ID=46314300

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007171A MX2013007171A (es) 2010-12-23 2010-12-23 Inductor de autofagia y terapia de combinacion inhibidora para el tratamiento de neoplasias.

Country Status (9)

Country Link
EP (1) EP2655619A4 (ja)
JP (1) JP2014507129A (ja)
KR (1) KR20130132956A (ja)
CN (1) CN103403161A (ja)
BR (1) BR112013015891A2 (ja)
CA (1) CA2821378A1 (ja)
MX (1) MX2013007171A (ja)
RU (1) RU2013134359A (ja)
WO (1) WO2012087336A1 (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6052540B2 (ja) * 2012-12-21 2016-12-27 国立大学法人福井大学 Ａｔｇ７変異体を用いたオートファジーの抑制方法
EA201690004A1 (ru) 2012-12-27 2016-07-29 Санофи Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение
KR101461916B1 (ko) 2013-11-04 2014-11-19 현대자동차 주식회사 커플드 토션 빔 액슬 타입 현가장치
WO2018143403A1 (ja) * 2017-02-03 2018-08-09 国立大学法人東北大学 複素環化合物
WO2018226776A1 (en) * 2017-06-08 2018-12-13 The Penn State Research Foundation Assay for monitoring autophagosome completion
JPWO2019112014A1 (ja) * 2017-12-07 2021-01-28 パール工業株式会社 選定分子の導入方法および阻害剤を含有する組成物
CN108103194B (zh) * 2017-12-27 2021-05-18 中国医学科学院药用植物研究所 一种抑制胃癌细胞mgc-803的靶点及其应用
KR102095749B1 (ko) * 2018-12-20 2020-04-01 충남대학교 산학협력단 S6k1 유전자 발현 억제제 또는 s6k1 단백질 활성 억제제를 유효성분으로 포함하는, 미토콘드리아 내 자가포식 장애로 발생되는 질병의 예방 또는 치료용 조성물
CN111593068B (zh) * 2019-01-28 2023-10-17 广州溯原生物科技股份有限公司 新型基因治疗载体pIRES-Rsirt2/4-Tet-nap的制备方法及应用
CN110592044B (zh) * 2019-07-26 2021-06-22 中国农业科学院蔬菜花卉研究所 蛋白激酶Fused编码基因及其在防治小菜蛾中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006078774A2 (en) * 2005-01-19 2006-07-27 The Trustees Of The University Of Pennsylvania Regulation of autophagy and cell survival
CA2616537A1 (en) * 2005-07-27 2007-02-01 University Of Florida Research Foundation, Inc. Small compounds that correct protein misfolding and uses thereof
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
UA95641C2 (en) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
US20100021420A1 (en) * 2006-07-14 2010-01-28 Astex Therapeutics Limited Combinations of pyrazole derivatives for the inhibition of cdks and gsk's
US8476431B2 (en) * 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
JP2012528588A (ja) * 2009-06-05 2012-11-15 ソル，ダイ‐ウ 単一またはマルチ標的遺伝子を抑制するマルチ−シストロンｓｈＲＮＡ発現カセット

Also Published As

Publication number Publication date
JP2014507129A (ja) 2014-03-27
BR112013015891A2 (pt) 2016-10-04
CA2821378A1 (en) 2012-06-28
EP2655619A4 (en) 2014-10-22
CN103403161A (zh) 2013-11-20
WO2012087336A1 (en) 2012-06-28
KR20130132956A (ko) 2013-12-05
EP2655619A1 (en) 2013-10-30
RU2013134359A (ru) 2015-01-27

Similar Documents

Publication Publication Date Title
MX2013007171A (es) Inductor de autofagia y terapia de combinacion inhibidora para el tratamiento de neoplasias.
TN2013000508A1 (en) Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
PL2694485T3 (pl) Kombinacja związku inhibitora akt i wemurafenibu do zastosowania w leczeniach terapeutycznych
MX351464B (es) El uso de un agonista del receptor 8 tipo toll para el tratamiento de enfermedades alérgicas.
MX348941B (es) Medios y metodos para trata y/o prevenir el cancer dependiente del ligando natural de receptor de aril-hidrocarburo.
MX369691B (es) Inhibidores de glutaminasa y métodos de empleo.
MX340290B (es) Uso terapéutico de un agonista de receptor tipo toll y terapia de combinación.
NZ587057A (en) Method of treating prostate cancer with the gnrh antagonist degarelix
CL2018000927A1 (es) Terapia combinada para el tratamiento de neoplasias malignas
SG195110A1 (en) Pirfenidone and anti-fibrotic therapy in selected patients
EA201491699A1 (ru) Лечение рака ингибиторами tor киназы
MX2020005533A (es) Nuevo proceso para la preparacion de derivados de piperidinilo-azetidina e intermediarios de los mismos, en donde dichos compuestos son inhibidores de mek.
MX350463B (es) Métodos de tratamiento del dolor.
MY176599A (en) Treatment of prostate cancer with tor kinase inhibitors
MX2013006319A (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek.
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
IN2014DN10404A (ja)
MX362111B (es) Un metodo para mejorar la funcion hepatica.
EP2584900A4 (en) COMBINATION THERAPY WITH CRYOSURGERY AND IMIQUIMOD WITH LOW DOSE THICKNESS FOR THE TREATMENT OF ACTIVE KERATOSIS
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
MX2011007384A (es) Terapias de combinacion para trastornos neoplásticos.
WO2012129145A8 (en) Nsclc combination therapy
BR112012018906A2 (pt) materiais e acessórios para a aplicação da terapia fotodinâmica antibacteriana
TN2013000247A1 (en) Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal